#LanAnhHandmade #youtube My name is Lan Anh, owner of youtube channel LanAnhHandmade. I live in Vietnam, a country in ...

Dr. Berenika Maciejewicz, a triple-doctor and an expert in longevity, leads the company’s interdisciplinary team to ...

The Open University of Kenya has announced 61 job opportunities for academic and administrative staff positions. In a notice ...

After five years, Nido Biosciences has reached the end of the road, closing its doors after its lead neurological disease candidate disappointed in a midstage study. Founded by 5AM Ventures’ 4:59 ...

The performance metrics speak volumes. The iShares Biotechnology ETF (NASDAQ: IBB) has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF (NASDAQ: XBI) has ...

Every year, TechCrunch’s Startup Battlefield pitch contest draws thousands of applicants. We whittle those applications down to the top 200 contenders, and of them, the top 20 compete on the big stage ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

“Biotech is making money again,” Mizuho Securities declared to cap off 2025. The sentiment was echoed across a handful of sector previews as analysts reflected on a turbulent year in life sciences.

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Healthcare and biotech stocks have had a rough run since the giddy heights of the Covid pandemic. But now could be the perfect time to consider investing in these beaten-down but high-growth sectors.

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

Wave Life Sciences offers an exciting new obesity treatment that can translate to big gains ahead, according to Wells Fargo. The bank reiterated the Singapore-based biotech name as overweight and ...